氯吡格雷抵抗与细胞色素P2C19基因多态性的相关性研究进展

摘要

氯吡格雷是目前临床治疗中常用抗血小板药物之一,但应用常规剂量的氯吡格雷治疗后仍有部分患者出现血栓性不良心血管事件,即发生了氯吡格雷抵抗现象.产生抵抗的原因既多且杂,细胞色素P2C19(CYP2C 19)基因多态性是影响氯吡格雷抵抗最重要的内因之一,研究氯吡格雷抵抗与CYP2C19基因多态性之间的相关性,可以预测药物疗效,有利于临床上氯吡格雷个性化用药方案的确定,从而提高临床治疗效果,使患者受益.%Clopidogrel is one of the commonly used antiplatelet drugs.Thrombotic cardiovascular events may occur in some patients with clopidogrel therapy due to clopidogrel resistance.There are complex reasons related to clopidogrel resistance,cytochrome P2C19 (CYP2C19) gene polymorphism is one of the most important endopathic factors.The relativity between clopidogrel resistance and CYP2C19 gene polymorphism can be a predictor of personalized clopidogrel regimen to help improve the clinical benefit.